Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Devlife
Yokohama, Kanagawa, Japandevlife.co.jp ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DevLife is a clinical-stage biotechnology company based in Japan that focuses on developing novel small molecule immunotherapies for cancer. The company's lead asset, DL-001, is a potent and selective Toll-like receptor 7 (TLR7) agonist designed to activate the innate immune system to induce anti-tumor activity. DevLife is currently evaluating DL-001 in a Phase 1/2 clinical trial for patients with advanced or metastatic solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on Devlife.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Devlife.